Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Sundstrøm S[au]:

S.H. Sundstrøm responds. Sundstrøm SH et al. Tidsskr Nor Laegeforen. (2018)

Detecting spatial regimes in ecosystems. Sundstrom SM et al. Ecol Lett. (2017)

A method to detect discontinuities in census data. Barichievy C et al. Ecol Evol. (2018)

Search results

Items: 1 to 50 of 107

1.

An information theory-based approach to assessing spatial patterns in complex systems.

Eason T, Ching-Chuang W, Sundstrom S, Cabezas H.

Entropy (Basel). 2019 Feb;21(2):1-182. doi: 10.3390/e21020182.

PMID:
31402835
2.

Early Warnings for State Transitions.

Roberts CP, Twidwell D, Burnett JL, Donovan VM, Wonkka CL, Bielski CL, Garmestani AS, Angeler DG, Tarsha Eason, Allred B, Jones MO, Naugle DE, Sundstrom SM, Allen CR.

Rangel Ecol Manag. 2018 Nov;71(6):659-670. doi: 10.1016/j.rama.2018.04.012.

PMID:
30800013
3.

Prosodic aspects of repetition in Swedish-speaking children with developmental language disorder.

Sundström S, Lyxell B, Samuelsson C.

Int J Speech Lang Pathol. 2018 Dec 17:1-12. doi: 10.1080/17549507.2018.1508500. [Epub ahead of print]

4.

A method to detect discontinuities in census data.

Barichievy C, Angeler DG, Eason T, Garmestani AS, Nash KL, Stow CA, Sundstrom S, Allen CR.

Ecol Evol. 2018 Sep 20;8(19):9614-9623. doi: 10.1002/ece3.4297. eCollection 2018 Oct.

5.

S.H. Sundstrøm responds.

Sundstrøm SH.

Tidsskr Nor Laegeforen. 2018 Sep 3;138(13). doi: 10.4045/tidsskr.18.0593. Print 2018 Sep 4. English, Norwegian. No abstract available.

6.

The distribution and role of functional abundance in cross-scale resilience.

Sundstrom SM, Angeler DG, Barichievy C, Eason T, Garmestani A, Gunderson L, Knutson M, Nash KL, Spanbauer T, Stow C, Allen CR.

Ecology. 2018 Nov;99(11):2421-2432. doi: 10.1002/ecy.2508. Epub 2018 Sep 28.

PMID:
30175443
7.

Prosodic and segmental aspects of nonword repetition in 4- to 6-year-old children who are deaf and hard of hearing compared to controls with normal hearing.

Sundström S, Löfkvist U, Lyxell B, Samuelsson C.

Clin Linguist Phon. 2018;32(10):950-971. doi: 10.1080/02699206.2018.1469671. Epub 2018 May 3.

PMID:
29723069
8.

Enhancing quantitative approaches for assessing community resilience.

Chuang WC, Garmestani A, Eason TN, Spanbauer TL, Fried-Petersen HB, Roberts CP, Sundstrom SM, Burnett JL, Angeler DG, Chaffin BC, Gunderson L, Twidwell D, Allen CR.

J Environ Manage. 2018 May 1;213:353-362. doi: 10.1016/j.jenvman.2018.01.083.

9.

Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement.

Valan CD, Slagsvold JE, Halvorsen TO, Herje M, Bremnes RM, Brunsvig PF, Brustugun OT, Fløtten Ø, Levin N, Sundstrøm SH, Grønberg BH.

Anticancer Res. 2018 Feb;38(2):871-876.

PMID:
29374714
10.

Detecting spatial regimes in ecosystems.

Sundstrom SM, Eason T, Nelson RJ, Angeler DG, Barichievy C, Garmestani AS, Graham NA, Granholm D, Gunderson L, Knutson M, Nash KL, Spanbauer T, Stow CA, Allen CR.

Ecol Lett. 2017 Jan;20(1):19-32. doi: 10.1111/ele.12709.

11.

Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer.

Halvorsen TO, Herje M, Levin N, Bremnes RM, Brustugun OT, Fløtten Ø, Kaasa S, Sundstrøm S, Grønberg BH.

Lung Cancer. 2016 Dec;102:9-14. doi: 10.1016/j.lungcan.2016.10.003. Epub 2016 Oct 15.

PMID:
27987595
12.

Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer.

Halvorsen TO, Sundstrøm S, Fløtten Ø, Brustugun OT, Brunsvig P, Aasebø U, Bremnes RM, Kaasa S, Grønberg BH.

Acta Oncol. 2016 Nov;55(11):1349-1354. Epub 2016 Aug 23.

PMID:
27549509
13.

Body size distributions signal a regime shift in a lake ecosystem.

Spanbauer TL, Allen CR, Angeler DG, Eason T, Fritz SC, Garmestani AS, Nash KL, Stone JR, Stow CA, Sundstrom SM.

Proc Biol Sci. 2016 Jun 29;283(1833). pii: 20160249. doi: 10.1098/rspb.2016.0249.

14.

Resisting Resilience Theory: A Response to Connell and Ghedini.

Sundstrom SM, Allen CR, Gunderson L.

Trends Ecol Evol. 2016 Jun;31(6):412-413. doi: 10.1016/j.tree.2016.03.014. Epub 2016 Apr 13. No abstract available.

PMID:
27085198
15.

Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer.

Grønberg BH, Halvorsen TO, Fløtten Ø, Brustugun OT, Brunsvig PF, Aasebø U, Bremnes RM, Tollåli T, Hornslien K, Aksnessæther BY, Liaaen ED, Sundstrøm S; Norwegian Lung Cancer Study Group.

Acta Oncol. 2016 May;55(5):591-7. doi: 10.3109/0284186X.2015.1092584. Epub 2015 Oct 23.

PMID:
26494411
16.

Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III.

Varughese RK, Lind-Landström T, Habberstad AH, Salvesen Ø, Haug CS, Sundstrøm S, Torp SH.

J Clin Pathol. 2016 Jan;69(1):26-34. doi: 10.1136/jclinpath-2015-202983. Epub 2015 Jul 17.

PMID:
26188054
17.

How Do Elderly Poor Prognosis Patients Tolerate Palliative Concurrent Chemoradiotherapy for Locally Advanced Non-Small-Cell Lung Cancer Stage III? A Subset Analysis From a Clinical Phase III Trial.

Strøm HH, Bremnes RM, Sundstrøm SH, Helbekkmo N, Aasebø U.

Clin Lung Cancer. 2015 May;16(3):183-92. doi: 10.1016/j.cllc.2014.08.005. Epub 2014 Nov 13.

18.

Differences in phonologic and prosodic abilities in children with phonological language impairment and phonological-grammatical language impairment assessed with non-word repetition.

From Å, Sundström S, Samuelsson C.

Logoped Phoniatr Vocol. 2016 Jul;41(2):66-76. doi: 10.3109/14015439.2014.982171. Epub 2014 Dec 1.

PMID:
25436899
19.

[Occupational lung cancer in Sør-Trøndelag county].

Slåstad S, Leira HL, Aas O, Amundsen T, Sørhaug S, Sundstrøm S, Grønberg BH, Hilt B.

Tidsskr Nor Laegeforen. 2014 Oct 28;134(20):1943-7. doi: 10.4045/tidsskr.13.0900. eCollection 2014 Oct 28. Norwegian.

20.

Poor prognosis patients with inoperable locally advanced NSCLC and large tumors benefit from palliative chemoradiotherapy: a subset analysis from a randomized clinical phase III trial.

Strøm HH, Bremnes RM, Sundstrøm SH, Helbekkmo N, Aasebø U.

J Thorac Oncol. 2014 Jun;9(6):825-33. doi: 10.1097/JTO.0000000000000184.

21.

Discontinuities, cross-scale patterns, and the organization of ecosystems.

Nash KL, Allen CR, Angeler DG, Barichievy C, Eason T, Garmestani AS, Graham NA, Granholm D, Knutson M, Nelson RJ, Nyström M, Stow CA, Sundstrom SM.

Ecology. 2014 Mar;95(3):654-67.

PMID:
24804450
22.

Histopathology and prognosis in human meningiomas.

Backer-Grøndahl T, Moen BH, Sundstrøm SH, Torp SH.

APMIS. 2014 Sep;122(9):856-66. doi: 10.1111/apm.12248. Epub 2014 Apr 3.

PMID:
24698127
23.

[Breast-preserving surgery--always the right choice?].

Sundstrøm SH.

Tidsskr Nor Laegeforen. 2013 Aug 20;133(15):1551. doi: 10.4045/tidsskr.13.0837. Norwegian. No abstract available.

24.

Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group.

Strøm HH, Bremnes RM, Sundstrøm SH, Helbekkmo N, Fløtten O, Aasebø U.

Br J Cancer. 2013 Sep 17;109(6):1467-75. doi: 10.1038/bjc.2013.466. Epub 2013 Aug 20.

25.

Can dogs smell lung cancer? First study using exhaled breath and urine screening in unselected patients with suspected lung cancer.

Amundsen T, Sundstrøm S, Buvik T, Gederaas OA, Haaverstad R.

Acta Oncol. 2014 Mar;53(3):307-15. doi: 10.3109/0284186X.2013.819996. Epub 2013 Aug 19.

PMID:
23957595
26.

Expression and clinical significance of the proliferation marker minichromosome maintenance protein 2 (Mcm2) in diffuse astrocytomas WHO grade II.

Lind-Landström T, Varughese RK, Sundstrøm S, Torp SH.

Diagn Pathol. 2013 Apr 24;8:67. doi: 10.1186/1746-1596-8-67.

27.

Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007.

Walters S, Maringe C, Coleman MP, Peake MD, Butler J, Young N, Bergström S, Hanna L, Jakobsen E, Kölbeck K, Sundstrøm S, Engholm G, Gavin A, Gjerstorff ML, Hatcher J, Johannesen TB, Linklater KM, McGahan CE, Steward J, Tracey E, Turner D, Richards MA, Rachet B; ICBP Module 1 Working Group.

Thorax. 2013 Jun;68(6):551-64. doi: 10.1136/thoraxjnl-2012-202297. Epub 2013 Feb 11.

28.

Primary human glioblastomas - prognostic value of clinical and histopathological parameters.

Habberstad AH, Lind-Landström T, Sundstrøm S, Torp SH.

Clin Neuropathol. 2012 Sep-Oct;31(5):361-8.

PMID:
22939176
29.

A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer.

Grønberg BH, Ciuleanu T, Fløtten Ø, Knuuttila A, Abel E, Langer SW, Krejcy K, Liepa AM, Munoz M, Hahka-Kemppinen M, Sundstrøm S.

Lung Cancer. 2012 Oct;78(1):63-9. doi: 10.1016/j.lungcan.2012.07.007. Epub 2012 Aug 20.

PMID:
22917813
30.

Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma.

Røe OD, Szulkin A, Anderssen E, Flatberg A, Sandeck H, Amundsen T, Erlandsen SE, Dobra K, Sundstrøm SH.

PLoS One. 2012;7(8):e40521. doi: 10.1371/journal.pone.0040521. Epub 2012 Aug 8.

31.

Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group.

Fløtten Ø, Grønberg BH, Bremnes R, Amundsen T, Sundstrøm S, Rolke H, Hornslien K, Wentzel-Larsen T, Aasebø U, von Plessen C.

Br J Cancer. 2012 Jul 24;107(3):442-7. doi: 10.1038/bjc.2012.284. Epub 2012 Jul 3.

32.

Did survival improve after the implementation of intraoperative neuronavigation and 3D ultrasound in glioblastoma surgery? A retrospective analysis of 192 primary operations.

Sæther CA, Torsteinsen M, Torp SH, Sundstrøm S, Unsgård G, Solheim O.

J Neurol Surg A Cent Eur Neurosurg. 2012 Mar;73(2):73-8. doi: 10.1055/s-0031-1297247. Epub 2012 Mar 30.

PMID:
22467479
33.

Species, functional groups, and thresholds in ecological resilience.

Sundstrom SM, Allen CR, Barichievy C.

Conserv Biol. 2012 Apr;26(2):305-14. doi: 10.1111/j.1523-1739.2011.01822.x.

PMID:
22443132
34.

Prognostic value of histological features in diffuse astrocytomas WHO grade II.

Lind-Landström T, Habberstad AH, Sundstrøm S, Torp SH.

Int J Clin Exp Pathol. 2012;5(2):152-8. Epub 2012 Feb 12.

35.

Astroblastoma - a case report of a rare neuroepithelial tumor with complete remission after chemotherapy.

Bergkåsa M, Sundstrøm S, Gulati S, Torp SH.

Clin Neuropathol. 2011 Nov-Dec;30(6):301-6.

36.

Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial.

Brunsvig PF, Kyte JA, Kersten C, Sundstrøm S, Møller M, Nyakas M, Hansen GL, Gaudernack G, Aamdal S.

Clin Cancer Res. 2011 Nov 1;17(21):6847-57. doi: 10.1158/1078-0432.CCR-11-1385. Epub 2011 Sep 14.

37.

Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy.

Grønberg BH, Sundstrøm S, Kaasa S, Bremnes RM, Fløtten O, Amundsen T, Hjelde HH, Plessen Cv, Jordhøy M.

Eur J Cancer. 2010 Aug;46(12):2225-34. doi: 10.1016/j.ejca.2010.04.009. Epub 2010 May 12.

PMID:
20471248
38.

Potentially curative radiotherapy for non-small-cell lung cancer in Norway: a population-based study of survival.

Strand TE, Brunsvig PF, Johannessen DC, Sundstrøm S, Wang M, Hornslien K, Bremnes RM, Stensvold A, Garpestad O, Norstein J.

Int J Radiat Oncol Biol Phys. 2011 May 1;80(1):133-41. doi: 10.1016/j.ijrobp.2010.01.050. Epub 2010 May 6.

PMID:
20452137
39.

[Recurrence and survival after surgical treatment of lung cancer].

Hjelde H, Sundstrøm S, Ødegård A, Hatlinghus S, Abusland AB, Haaverstad R.

Tidsskr Nor Laegeforen. 2010 Jan 14;130(1):25-8. doi: 10.4045/tidsskr.09.0689. Norwegian.

40.

The non-proteolytic house dust mite allergen Der p 2 induce NF-kappaB and MAPK dependent activation of bronchial epithelial cells.

Osterlund C, Grönlund H, Polovic N, Sundström S, Gafvelin G, Bucht A.

Clin Exp Allergy. 2009 Aug;39(8):1199-208. doi: 10.1111/j.1365-2222.2009.03284.x. Epub 2009 May 26.

PMID:
19486032
41.

Some observations on airborne particles in the critical areas of a blow-fill-seal machine.

Sundström S, Ljungqvist B, Reinmüller B.

PDA J Pharm Sci Technol. 2009 Jan-Feb;63(1):71-80.

PMID:
19455943
42.

Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.

Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S.

J Clin Oncol. 2009 Jul 1;27(19):3217-24. doi: 10.1200/JCO.2008.20.9114. Epub 2009 May 11.

PMID:
19433683
43.

Assessing quality of life in a randomized clinical trial: correcting for missing data.

Gunnes N, Seierstad TG, Aamdal S, Brunsvig PF, Jacobsen AB, Sundstrøm S, Aalen OO.

BMC Med Res Methodol. 2009 Apr 30;9:28. doi: 10.1186/1471-2288-9-28.

44.

Chemotherapy and quality of life in NSCLC PS 2 patients.

Helbekkmo N, Strøm HH, Sundstrøm SH, Aasebø U, Von Plessen C, Bremnes RM; Norwegian Lung Cancer Study Group.

Acta Oncol. 2009;48(7):1019-25. doi: 10.1080/02841860902795240.

PMID:
19274496
45.

Phosphorylation site mapping of endogenous proteins: a combined MS and bioinformatics approach.

Sundstrom JM, Sundstrom CJ, Sundstrom SA, Fort PE, Rauscher RL, Gardner TW, Antonetti DA.

J Proteome Res. 2009 Feb;8(2):798-807. doi: 10.1021/pr8005556.

46.

Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study.

Hillerdal G, Sorensen JB, Sundström S, Riska H, Vikström A, Hjerpe A.

J Thorac Oncol. 2008 Nov;3(11):1325-31. doi: 10.1097/JTO.0b013e31818b174d.

47.

Photodynamic therapy with 5-aminolaevulinic acid, dimethylsulfoxide and curettage in basal cell carcinoma: a 6-year clinical and histological follow-up.

Christensen E, Skogvoll E, Viset T, Warloe T, Sundstrøm S.

J Eur Acad Dermatol Venereol. 2009 Jan;23(1):58-66. doi: 10.1111/j.1468-3083.2008.02946.x. Epub 2008 Sep 18.

PMID:
18803580
48.

Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial.

Hermes A, Bergman B, Bremnes R, Ek L, Fluge S, Sederholm C, Sundstrøm S, Thaning L, Vilsvik J, Aasebø U, Sörenson S.

J Clin Oncol. 2008 Sep 10;26(26):4261-7. doi: 10.1200/JCO.2007.15.7545.

PMID:
18779613
49.

Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.

Santoro A, O'Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz-Ares L, Sundstrom S, Liu Y, Ripoche V, Blatter J, Visseren-Grul CM, Manegold C.

J Thorac Oncol. 2008 Jul;3(7):756-63. doi: 10.1097/JTO.0b013e31817c73d6.

50.

A prospective phase II study: high-dose pemetrexed as second-line chemotherapy in small-cell lung cancer.

Grønberg BH, Bremnes RM, Aasebø U, Brunsvig P, Fløtten O, Amundsen T, von Plessen C, Wang M, Sundstrøm S; Norwegian Lung Cancer Study Group.

Lung Cancer. 2009 Jan;63(1):88-93. doi: 10.1016/j.lungcan.2008.04.003. Epub 2008 Jun 6.

PMID:
18538889

Supplemental Content

Loading ...
Support Center